Skip to Content

Sophiris Bio Inc SPHS

Rating as of

Morningstar’s Analysis

There is no Morningtar’s Analysis data available.

Company Profile

Business Description

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

Contact
1258 Prospect Street
La Jolla, CA, 92037, Canada
T +1 858 777-1760
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2019
Fiscal Year End Dec 31, 2019
Stock Type
Employees 6